Please assess the completion status of the following clinical trial:

Trial Title: Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Locally advanced or metastatic, histologically proven clear cell or papillary cell renal carcinoma.~2. Primary tumour surgically removed.~3. Progressive disease~4. At least four weeks from any previous therapy for renal cancer.~5. Fit for first or second line immunotherapy with subcutaneous low dose IL-2~6. Measurable disease~7. Aged 18 years or more.~8. Patients must comply with the following:~   * Karnofsky score ≥ 80%~  * Corrected calcium ≥ 10 g/dL (2.5 mmols/L)~9. Clinically immunocompetent~10. Free of clinically apparent autoimmune disease.~11. Haemoglobin ≥ 9 g/dL, total white cell count ≥ 3 x 10\^9/L and lymphocyte count ≥ 1 x 10\^9/dL~12. Serum creatinine up to 1.5 times upper limit of normal.~13. Bilirubin ≤ 2 mg% and an SGPT of ≤ 4 times the upper limit of normal.~14. Able to give written informed consent and to comply with the protocol.~15. Women must be either post menopausal, or rendered surgically sterile or, if of child bearing potential, must have been practising a reliable form of contraception (oral contraception + a barrier method) for at least three months prior to the first dose of TroVax® and must continue while they are being treated with TroVax®. Men must practise a reliable form of contraception while they are being treated with TroVax®.~16. No acute changes on 12-lead electrocardiogram (ECG)~17. Ejection fraction on echocardiogram ≥ 45%~Exclusion Criteria:~1. Previous immunotherapy with any schedule of IL-2.~2. Intercurrent serious infections within the 28 days prior to entry into the trial.~3. Life threatening illness unrelated to cancer.~4. Cerebral metastases on MRI scan.~5. History of allergic response to previous vaccinia vaccinations.~6. Participation in any other clinical trial of a licensed or unlicensed drug within the previous 30 days or during the course of this trial.~7. Previous malignancies within the last 10 years other than successfully treated squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone biopsy.~8. Previous history of major psychiatric disorder requiring hospitalisation or any current psychiatric disorder that would impede the patient's ability to provide informed consent or to comply with the protocol.~9. Known allergy to egg proteins~10. Chronic oral corticosteroid use unless prescribed as replacement therapy in the case of adrenal insufficiency.~11. Known to test positive for HIV or hepatitis B or C~12. Known hypersensitivity to neomycin~13. Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TroVax (Type: EXPERIMENTAL): TroVax given as first or second line treatment in conjuntion with low dose IL-2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete